A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Clinical trial NCT05388669 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05388669
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-05
- Primary completion
- 2024-01-03
- Enrollment
- 418
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.